Results for tag: "Ustekinumab"

Ustekinumab is a biologic drug used to treat moderate to severe plaque psoriasis, a chronic skin condition. It is a human monoclonal antibody that works by targeting two proteins, interleukin-12 and interleukin-23, which are involved in the inflammation and overproduction of skin cells that characterize psoriasis. Ustekinumab is administered as an intravenous or subcutaneous injection. It is the first biologic drug approved for the treatment of psoriasis in adults and adolescents aged 12 and older. Ustekinumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2009. It is one of several biologic drugs used to treat psoriasis, and is generally considered to be a safe and effective treatment option. It is often used in combination with other treatments, such as topical medications, phototherapy, and systemic medications. Ustekinumab is marketed by several companies, including Janssen Biotech, Inc., Merck & Co., Inc., and Sun Pharmaceutical Industries Ltd. Show Less Read more